Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.

Int J Clin Oncol · 2025 · PMC11700049 · PMID 39549218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although OS analyses did not reach statistical significance at the final analysis of JAVELIN Renal 101, results for PFS and ORR consistently favored avelumab + axitinib and support outcomes from the J-DART2 study in clinical practice in Japan [ 27 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.